![What's Happening In PWS Research? [2021 CONFERENCE VIDEO]](https://www.fpwr.org/hubfs/Blog_Images/Whats-Happening-In-PWS-Research-feature.jpg)
In this 67‑minute video, Dr. Theresa Strong and the FPWR Research Team share highlights of projects we are currently advancing. The session includes Q&A from participants in the 2021 FPWR Virtual Conference.
Source: FPWR Blog
|
Published: January 1 2022 - 12:00 PM
Research at a Glance: A new test, funded in part by FPWR, has been designed to simultaneously screen newborns for three rare genetic disorders In a recent study, the test was found to be feasible, reliable, and scalable Screening for Prader Willi, Angelman, and Dup15q syndromes using the new test...
Source: FPWR Blog
|
Published: January 1 2022 - 08:50 AM
Soleno Therapeutics has provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS).
Source: FPWR Blog
|
Published: January 1 2022 - 08:47 AM
Levo Therapeutics, announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for LV-101 (intranasal carbetocin) as a treatment for hyperphagia, anxiousness, and distress associated with PWS.
Source: FPWR Blog
|
Published: January 1 2022 - 06:51 AM
Saniona, a clinical-stage biopharmaceutical company focused on rare diseases, has announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS).
Source: FPWR Blog
|
Published: January 1 2022 - 12:00 PM
